Increased risk of arterial thromboembolic events with combination lenalidomide/dexamethasone therapy for multiple myeloma
Sign Up to like & getrecommendations! Published in 2017 at "Expert Review of Anticancer Therapy"
DOI: 10.1080/14737140.2017.1330153
Abstract: ABSTRACT Introduction: Cancer associated thrombosis is a leading cause of morbidity and mortality. Research and guidelines have focused on venous thromboembolic events (VTE). Within the past decade, combination lenalidomide and dexamethasone has become a standard… read more here.
Keywords: therapy; combination lenalidomide; thromboembolic events; lenalidomide dexamethasone ... See more keywords
Oncolytic herpes simplex virus type 1 (HSV‐1) in combination with lenalidomide for plasma cell neoplasms
Sign Up to like & getrecommendations! Published in 2020 at "British Journal of Haematology"
DOI: 10.1111/bjh.17173
Abstract: Oncolytic viruses exert an anti‐tumour effect through two mechanisms: direct oncolytic and indirect immune‐mediated mechanisms. Although oncolytic herpes simplex virus type 1 (HSV‐1) has been approved for melanoma treatment and is being examined for its… read more here.
Keywords: hsv; effect; combination lenalidomide; type ... See more keywords
A phase Ib study of atezolizumab (atezo) alone or in combination with lenalidomide or pomalidomide and/or daratumumab in patients (pts) with multiple myeloma (MM).
Sign Up to like & getrecommendations! Published in 2017 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2017.35.15_suppl.tps8053
Abstract: TPS8053Background: The advent of proteasome inhibitors and immunomodulatory drugs (IMiDs) have significantly improved outcomes in MM, and the first monoclonal antibodies for MM have been recently a... read more here.
Keywords: alone combination; atezolizumab atezo; combination lenalidomide; study atezolizumab ... See more keywords
Combination of lenalidomide and vitamin D enhances MOR202-mediated cytotoxicity of macrophages: It takes three to tango
Sign Up to like & getrecommendations! Published in 2019 at "Oncotarget"
DOI: 10.18632/oncotarget.26531
Abstract: Although multiple myeloma (MM) has become more treatable in the past decade by application of proteasome inhibitors (PI) and immunomodulatory drugs (IMiDs) [1], there is an urgent need for development of novel treatment alternatives. Monoclonal… read more here.
Keywords: combination; lenalidomide vitamin; vitamin enhances; antibody ... See more keywords